SubHero Banner

Totect® (dexrazoxane) – New indication

November 2, 2020 - The FDA approved Clinigen’s Totect (dexrazoxane), for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control.

Download PDF